Wilbur Gantz will not stand for re-election to the board of Aevi Genomic Medicine Inc. at the 2018 annual stockholders meeting.

Gantz, who informed the company March 19 that he plans to retire, will continue to serve until his current term expires at the annual meeting.

Gantz has been a director of the Pennsylvania-based clinical stage biopharmaceutical company since October 2013.